GSK plc - Asset Resilience Ratio
GSK plc (G1SK34) has an Asset Resilience Ratio of 5.57% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how GSK plc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down GSK plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$3.40 Billion | 5.56% |
| Short-term Investments | R$9.00 Million | 0.01% |
| Total Liquid Assets | R$3.41 Billion | 5.57% |
Asset Resilience Insights
- Limited Liquidity: GSK plc maintains only 5.57% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
GSK plc Industry Peers by Asset Resilience Ratio
Compare GSK plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ono Pharmaceutical Co. Ltd
MU:ON4 |
Drug Manufacturers - General | 0.55% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 5.03% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367 |
Drug Manufacturers - General | 32.14% |
Annual Asset Resilience Ratio for GSK plc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for GSK plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.66% | R$2.77 Billion | R$59.46 Billion | -2.53pp |
| 2023-12-31 | 7.19% | R$4.24 Billion | R$59.01 Billion | -4.44pp |
| 2022-12-31 | 11.64% | R$7.00 Billion | R$60.15 Billion | +11.56pp |
| 2021-12-31 | 0.08% | R$61.00 Million | R$79.10 Billion | -0.02pp |
| 2020-12-31 | 0.10% | R$78.00 Million | R$80.43 Billion | 0.00pp |
| 2019-12-31 | 0.10% | R$79.00 Million | R$79.69 Billion | -0.05pp |
| 2018-12-31 | 0.14% | R$84.00 Million | R$58.07 Billion | -- |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more